Kornimate/medical-research-clean huggingface dataset:
community based obesity prevention among blacks

Conditions: Obesity

Summary: the purpose of this study is to examine whether pedometer step count recommendations (10,000 steps/day versus an adaptive recommendation) are differentially associated with the primary outcome of adherence to the pedometer-based physical activity regimen and the secondary outcomes of change in physical activity and body mass index (bmi).

long-term promotion of physical activity is necessary to achieve obesity prevention. this represents a particular challenge for our intervention design, as few studies have demonstrated positive long-term physical activity promotion outcomes among black women. we have demonstrated the utility of pedometers among low income, ethnically diverse populations. the efficacy of pedometer utilization for the prevention of weight gain, however, hinges on long-term utilization of the devices. we hypothesize that recommendation for the step count attainment may affect individual's long-term utilization of pedometers, as well as physical activity levels and bmi. this study is a 24-week experimental trial to examine whether intervention recommendations promote long-term adherence to a pedometer-based physical activity regimen. a two-group, block design will be used in the proposed study. eligible women will be randomly assigned to one of two experimental conditions (n=75 per condition): 1) receiving a 10,000 steps/day recommendation and 3 health education sessions or 2) receiving an adaptive recommendation and an obesity prevention intervention. the adaptive step recommendation will update participants' recommended step counts, starting at 7,000 steps/day, then 8,000 steps/day, then finally 10,000 steps/day. participants in the adaptive recommendation group will be provided with 3 educational sessions and will be asked to report their daily progress on weight maintenance goals via text message. participants will be provided pedometers and will be asked to wear them every day of the 24-week trial period. assessments (including self-report survey and anthropometric measurements) will be conducted at baseline, 12 weeks and 24 weeks post-baseline.

Eligibility criteria:
inclusion criteria: * female * ages 25 and over * bmi 25 and over * english fluency * not currently pregnant * no restrictions to ambulatory activity exclusion criteria: * current pregnancy * childbearing in the past 12 months * history of myocardial infarction or stroke in last 2 years

Keywords: obesity women's health minority health obesity prevention
sp-303t applied to the skin of patients with herpes simplex virus (hsv) infection and aids who have not had success with acyclovir

Conditions: Herpes Simplex; HIV Infections

Summary: to evaluate the safety and tolerance of topically applied sp-303t in aids patients. to observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous acyclovir therapy. the lack of alternative treatments for herpes simplex virus infection in patients with aids and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. sp-303t has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication.

the lack of alternative treatments for herpes simplex virus infection in patients with aids and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. sp-303t has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication. patients receive 14 days (and up to 42 days) of treatment with topically applied sp-303t. sp-303t is applied directly onto herpes simplex virus lesions three times daily in a quantity sufficient to thinly cover the entire lesion, which may then be covered with an appropriate dressing, if needed. at the end of the treatment period, patients enter a follow-up period of 2 weeks.

Eligibility criteria:
inclusion criteria patients must have: * hiv-1 infection. * aids. * chronic mucocutaneous herpes simplex virus (hsv) infection, with one or more lesions unresponsive to oral acyclovir therapy. * no uncontrolled infections other than hsv. * sufficient mental status to understand the purpose of the study and to comply with study requirements. * sufficient general health to be an outpatient and to come to the clinic for required follow-up visits. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * known hypersensitivity or allergy to citrus fruits, black currant berries, and rose hips. * any disease condition that, in the opinion of the investigator, would interfere with evaluation of the study drug, affect patient compliance, or place the patient at increased risk. concurrent medication: excluded: * other unapproved investigational new drugs. * concurrent other therapy for herpes simplex virus (hsv) infection or medications with known activity against hsv. required: * a minimum of 10 days of prior oral acyclovir (at least 1 g daily) or 10 days of prior intravenous acyclovir (15 mg/kg daily).

Keywords: herpes simplex hiv-1 acquired immunodeficiency syndrome antiviral agents administration, topical
drug observance and side effects of cytoreductive drugs in pv and et patients

Conditions: Polycythemia Vera; Essential Thrombocythemia

Summary: patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.

during one year, all patients with pv or et followed in our centre, and who took a drug to treat their mpn, were identified. the investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug. after completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.

Eligibility criteria:
inclusion criteria: * patients with pv or et or smf * patients who took oral or sub-cutaneous drugs to treat their mpn. * patients who agreed to complete the questionnaire exclusion criteria: * patients with low risk pv or et who do not take treatment * patients unable to complete the questionnaire
outcomes of acute myeloid leukemia patients

Conditions: Acute Myeloid Leukemia

Summary: 1. to assess overall survival of aml patient. 2. to measure rate of disease free survival. 3. rate of non relapse mortality. 4. rate of complete remission . 5. percentage of refractory disease. 6. percentage of relapsed disease.

acute myeloid leukemia (aml) is a malignant disorder of the bone marrow which is characterized by malignant clonal expansion and differentiation arrest of myeloid progenitor cells. the etiology of aml is heterogeneous. in some patients, prior exposure to therapeutic, occupational or environmental dna-damaging agents is implicated, but most cases of aml remain without a clear etiology. the incidence of aml had been higher than that of the other three subtypes of leukemia ( \[all\], \[cml\], and \[cll\])\& accounts for the highest percentage (62%) of leukemic deaths. aml is primarily a disease of older adults. the age-adjusted incidence for those aged 65 years or older is 20.1 per 100,000 persones in comparison to 2.0 per 100,000 person-years for those younger than 65 years old. males are 1.2-1.6 times more likely to develop aml during their lifetime as evidenced by population-based studies in the us, uk, canada, denmark, australia and algeria. aml is one of the most common form of hematological malignancy in adults and has the shortest survival (5-year survival = 24%). curative therapies, including intensive chemotherapy and allogeneic stem cell transplantation, are generally applicable to a minority of patients who are younger and fit, while most older individuals exhibit poor prognosis and survival. differences in patient outcomes are influenced by disease characteristics, access to care including active therapies and supportive care, and other factors. after many years without therapeutic advances, several new therapies have been approved and are expected to impact patient outcomes, especially for older patients and those with refractory disease.

Eligibility criteria:
inclusion criteria: * aml patients, aged more than 18yrs and received chemotherapy (aggressive or palliative). exclusion criteria: * patients less than 18years old.
development of a refined version of the stroke rehabilitation assessment of movement scale for stroke patients

Conditions: Cerebrovascular Accidents

Summary: we will employ modern test theory (i.e., rasch model) to refine the stroke rehabilitation assessment of movement instrument (stream), which will be called the refined version of the stream, r-stream).

we will employ modern test theory (i.e., rasch model) to refine the stroke rehabilitation assessment of movement instrument (stream), which will be called the refined version of the stream, r-stream). we will devote three years to complete this project. in the first year, the item pool (about 45 items) based on the stream will be developed and 12-15 items will be selected from the pool to construct the r-stream. a therapist will administer all the items on 300 stroke patients. the other therapist will administer these items on 60 patients randomly selected from the 300 patients to examine interrater reliability of each item. the r-satream (4-5 items for each of the three subscales) will be constructed based on the inter-rater reliability and rasch analysis of these items, and the opinions of experts. in the second and third years of this project, the psychometric properties of the r-stream will be comprehensively established. we will also compare the psychometric properties of the r-stream and the stream in stroke patients to determine the psychometric properties and efficiency of the r-stream. the r-stream and stream will be used to longitudinally assess 120 patients (at three time points: at the conception of occupational therapy, one month after therapy, and 6 months after therapy) to compare the concurrent validity, predictive validity and responsiveness of the r-stream and stream. the test-retest reliability of both scales will be established on the other 60 chronic patients. it is anticipated that the r-stream will have sound psychometric properties, be simple and easy to use, and be able to be transformed to the interval level of measurement. the r-stream will best fit the need for simple measures in routine daily clinics. the r-stream will fit demands for both in-depth and efficient assessment. clinicians and researchers both will benefit from these new, scientific measurement tools for planning treatment, giving a prognosis, and assessing outcomes in stroke patients.

Eligibility criteria:
inclusion criteria: * patients with stroke ability to follow instructions exclusion criteria: * patients with other major diseases (e.g., cancer)

Keywords: stroke movement psychomterics
turkish translation, validity and reliability of the back pain and body posture assessment questionnaire

Conditions: Back Pain

Summary: the adult back pain and body posture assessment instrument (backpde-y), whose validity and reliability is planned, will be applied. this assessment scale will be translated into turkish by two native turkish speakers, one who is fluent in english.

220 people aged between 20-65 are planned to be included in the study. the data obtained from the study will be analyzed with appropriate statistical methods. in addition, a previously valid and reliable musculoskeletal system health inquiry (mis-ss) questionnaire, which evaluates the musculoskeletal problems of individuals included in the study, will be applied. it will be evaluated whether the results of the data obtained from the back pain and body posture assessment instrument for adults (backpde-y), which we have validated in turkish, and the results of the data obtained from the musculoskeletal health questionnaire (cis-ss) questionnaire are consistent with each other.

Eligibility criteria:
inclusion criteria: 18-65 years old willingness to participate in the study the mother tongue is turkish, being able to read and write, - it is between the ages of 18-65. exclusion criteria: those with a known or concomitant diagnosis of dementia not wanting to participate in the study patients with psychotic disorders, depression with psychotic symptoms, bipolar depression having a psychiatric illness with a serious psychiatric illness that may prevent the individual from understanding and completing the questionnaire
comparison of postoperative analgesic efficacy of caudal block versus spinal block with levobupivacaine for inguinal hernia in children

Conditions: Pain, Postoperative; Analgesia

Summary: neuraxial analgesia may improve postoperative outcomes for high-risk children who are susceptible to respiratory complications (e.g. post-operative apnea). the use of spinal anesthesia in infants and children requiring surgeries of the sub-umbilical regions is gaining considerable popularity worldwide. caudal analgesia along with general anesthesia is a very popular regional technique for prolonged postoperative analgesia in different pediatric surgical procedures where the surgical site is sub-umbilical. bupivacaine has been thoroughly studied, and a large global experience exists.

neuraxial analgesia may improve postoperative outcomes for high-risk children who are susceptible to respiratory complications (post-operative apnea). in this population, spinal anesthesia has been proposed as a means to reduce post-operative complications, especially apnea and post-operative respiratory dysfunction, although this utility has been questioned. spinal anesthesia modifies the neuroendocrine stress response, ensures a more rapid recovery, and may shorten hospital stay with fewer opioid-induced side effects. caudal analgesia along with general anesthesia is a very popular regional technique for prolonged postoperative analgesia in different pediatric surgical procedures where the surgical site is sub-umbilical. caudal anesthetics usually provide an-algesia for approximately 4-6 hours.

Eligibility criteria:
inclusion criteria: * age: 2-10 years. * weight: 15-40 kg. * sex: both males and females. * asa physical status: 1-ii. * operation: surgery below the umbilicus. exclusion criteria: * allergic reaction to local anesthetics (las). * local or systemic infection (risk of meningitis). * intracranial hypertension. * hydrocephalus. * intracranial hemorrhage. * coagulopathy. * hypovolemia. * parental refusal. * spinal deformities, such as spina bifida or myelomeningocele. * presence of a ventriculoperitoneal shunt because of a risk of shunt infection or dural leak.
comparison of operating room time length with the use of virtual surgical planning versus conventional treatment of mandible fractures

Conditions: Mandibular Fractures

Summary: the purpose of this trial is to compare operating room time between conventional treatment techniques \[without virtual surgical planning (vsp)\] versus treatment with use of virtual surgical planning (vsp) in patients that undergo mandibular reconstruction via open reduction internal fixation (orif).


Eligibility criteria:
inclusion criteria: * patient consent * complex mandible fracture (at least two fractures) that require orif of at least one fracture. this will exclude condylar fractures exclusion criteria: * patient refusal to participate in study * infected mandible fracture * closed reduction treatment of mandible fracture * fractures older than 2-3 weeks at the time of treatment * other concomitant mid-facial bone fractures (ie, zygomaticomaxillary complex (zmc), lefort fractures) * other etiologies than trauma of the mandibular fracture or pathologic fracture secondary to benign or malignant pathology that may require resection * pregnant patients will not be excluded from the study * co-morbidities (auto-immune disease, osteoporosis, titanium or metal allergy, uncontrolled diabetes (a1c greater than 8)
effects of statins on pro- and antioxidant status : link with statin-associated myopathy.

Conditions: Healthy

Summary: to evaluate the effects of a 8-week treatment with 80 mg/day simvastatin on prooxidant and antioxidant status at rest and after exercise, on mitochondrial respiration and calcium release in skeletal muscle, and on aérobic aptitude in 24 healthy male subjects.

day 1 : baseline oxidative status, lipid profile, exercice test, start of randomized treatment day 53 : muscular biopsy day 57 : follow-up oxidative status, lipid profile, exercice test, end of treatment

Eligibility criteria:
inclusion criteria: * bmi between 18.0 and 25.00 exclusion criteria: -

Keywords: persons
minimally invasive surgical treatment versus medical management for stroke patients with atrial fibrillation

Conditions: Atrial Fibrillation; Stroke

Summary: the purpose of this study is to compare a minimally invasive surgical procedure and medication management in stroke patients with atrial fibrillation. the two treatment options are a minimally invasive surgical procedure or the use of medications.

must have had a stroke or transient ischemic attack (tia) and have atrial fibrillation

Eligibility criteria:
inclusion criteria: * patients with a history of stroke and paroxysmal, persistent or permanent af. * ischemic stroke or tia with documented paroxysmal or persistent atrial fibrillation. a tia will meet inclusion criteria as a sudden-onset focal neurological symptom or sign lasting at least 10 minutes but less than 24 hours with or without evidence of acute brain ischemia on diffusion weighted mri imaging. * eligible symptoms include hemiplegia or hemiparesis, monoplegia, or language disturbance other than isolated dysarthria. * symptoms that will not qualify as tia include transient monocular blindness in both eyes, dysarthria, vertigo,isolated sensory symptoms, confusion, memory loss, nonspecific complaints of dizziness, or syncope. exclusion criteria: * recent stroke (\< 1 month). * age \ 80 years; ejection fraction \< 25%• presence of left atrial appendage thrombus on ct or echocardiography * previous empyema or thoracic surgery, preventing access to the pulmonary veins via thoracoscopy. * left atrial diameter \> 55mm. * contraindication to anticoagulation with coumadin. * mitral insufficiency (\> 2+) * • • contraindications to mri * •artificial heart valve prosthesis * aneurysm clips * implanted drug infusion device or pump * any type of neurotranstimulator * any type of bone growth stimulator * cochlear implants or inner ear prosthesis * any intravascular coils, filters, or stents * shrapnel or bullets * other metallic implants or devices specify which * permanently tattooed eyeliner * are you pregnant or suspect to be pregnant?
study evaluating the coadministration of begacestat and donepezil

Conditions: Healthy Subjects

Summary: this study examines the cardiac effects (effects on the heart) of administering donepezil and begacestat together to healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy * men and women of non-childbearing potential * non smoker or smoker of \<10 cigarettes per day and able to refrain from smoking during study * 18-50 years old exclusion criteria: * any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. * cardiac rhythm abnormalities * family history of cardiac risk factors

Keywords: alzheimer disease
real-world data of clinicopathological characteristics and management of breast cancer patients according to her2 status

Conditions: Early Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer

Summary: this is a data-driven, retrospective, longitudinal, population- based, observational, multi-centered study using secondary data captured from congruent electronic health records (ehrs).

patients with pathologically documented an initial breast cancer diagnostic (early breast cancer (bc) or locally advanced bc or de novo metastatic bc) with documented human epidermal growth factor receptor 2 (her2) and estrogen receptor (er)/progesterone receptor (pgr) expression status at the time of diagnosis. data to determine the primary endpoint is estimated to be derived from the ehrs of over 2,000 patients that have an initial diagnosis of early bc, or locally advanced bc, or de novo metastatic bc (mbc) between the 1st of january 2005 and the 31st of december 2021, and who had at least one subsequent relapse until the 31st of december 2021 in at least 10 clinical centers. the secondary endpoints utilize a larger collection of data from over 30,000 patients that have an initial diagnosis of early bc, or locally advanced bc, or de novo mbc between the 1st of january 2005 and the 31st of december 2021.

Eligibility criteria:
inclusion criteria: 1. male or female patients who have at least 18 years of age at enrollment. 2. patients with initial diagnosis of early bc or locally advanced bc or de novo mbc between the 1st of january 2005 and the 31st of december 2021 3. pathologically documented bc for: * her2 receptor expression with a validated assay according to american society of clinical oncology - college of american pathologists (asco/cap) recommendations at the time of diagnosis. her2 receptor expression can be: o her2-positive expression: defined as immunohistochemistry (ihc) 3+ or concurrent ihc 2+ with in situ hybridization (ish) positive or her2-low expression: defined as ihc 2+ with ish-negative or ihc 1+ with ish-negative or untested) or her2-negative expression: defined as ihc: 0. * estrogen receptor \[er\]- and/or progesterone receptor \[pgr\] with a validated assay according to asco/cap guidelines at the time of diagnosis during early and/or advanced setting. er/pgr expression can be: positive: er or pgr ≥1% or negative: er and pgr \<1% 4. electronic health records (ehrs), with guaranteed data to meet requisites, about clinicopathological characteristics, type of surgery, treatment management, disease outcomes, and genomic profile. centers that agree to participate must commit to include all subjects who meet the inclusion criteria, in order to reduce possible selection bias. exclusion criteria: 1. medical charts at hospital that cannot guarantee reliable and congruent ehrs. 2. if sufficient data cannot be obtained from ehrs.

Keywords: breast cancer real-world data her2 negative her2 positive her2 low artificial intelligence